Schroder Investment Management Group Sells 313,053 Shares of KalVista Pharmaceuticals, Inc. $KALV

Schroder Investment Management Group decreased its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 36.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 554,958 shares of the specialty pharmaceutical company’s stock after selling 313,053 shares during the quarter. Schroder Investment Management Group’s holdings in KalVista Pharmaceuticals were worth $6,274,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Invesco Ltd. lifted its stake in shares of KalVista Pharmaceuticals by 154.5% during the first quarter. Invesco Ltd. now owns 39,804 shares of the specialty pharmaceutical company’s stock valued at $459,000 after acquiring an additional 24,164 shares during the period. Emerald Advisers LLC raised its holdings in KalVista Pharmaceuticals by 15.6% during the 2nd quarter. Emerald Advisers LLC now owns 1,038,049 shares of the specialty pharmaceutical company’s stock worth $11,735,000 after purchasing an additional 139,859 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its holdings in KalVista Pharmaceuticals by 26.4% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 768,972 shares of the specialty pharmaceutical company’s stock worth $8,693,000 after purchasing an additional 160,759 shares during the last quarter. Woodline Partners LP lifted its position in KalVista Pharmaceuticals by 25.5% during the 1st quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company’s stock valued at $18,666,000 after purchasing an additional 329,068 shares during the period. Finally, Wellington Management Group LLP boosted its stake in shares of KalVista Pharmaceuticals by 2.8% in the 1st quarter. Wellington Management Group LLP now owns 126,268 shares of the specialty pharmaceutical company’s stock valued at $1,457,000 after purchasing an additional 3,405 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Cowen reissued a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday. JMP Securities lifted their target price on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a “market outperform” rating in a report on Friday, September 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, October 8th. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Thursday. Finally, Citizens Jmp decreased their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research note on Tuesday, November 11th. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $26.63.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 10,940 shares of the stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $147,143.00. Following the completion of the sale, the chief executive officer directly owned 416,189 shares in the company, valued at $5,597,742.05. This represents a 2.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Paul K. Audhya sold 5,296 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $71,231.20. Following the sale, the insider directly owned 131,831 shares in the company, valued at approximately $1,773,126.95. This represents a 3.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 31,329 shares of company stock valued at $432,485. Company insiders own 4.30% of the company’s stock.

KalVista Pharmaceuticals Stock Up 11.9%

Shares of NASDAQ:KALV opened at $16.40 on Friday. The company has a 50 day moving average price of $12.21 and a two-hundred day moving average price of $12.97. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The company has a market capitalization of $829.02 million, a PE ratio of -4.15 and a beta of -0.14. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $17.28.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $0.04. The firm had revenue of $13.69 million during the quarter, compared to analyst estimates of $6.03 million. Analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).